# Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

> **NCT05725902** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 12 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Etavopivat

## Key facts

- **NCT ID:** NCT05725902
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-09
- **Primary completion:** 2026-03-09
- **Final completion:** 2026-03-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05725902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05725902, "Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05725902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*